Replies to post #23648 on Radient Pharmaceuticals Corporation fka RXPC

[Gold Seeker]

Living, they will never file a PMA. It would be a waste of time and money. This is all about scamming the investors and you don't put everything on the line and get a FDA rejection. That would be stupid. Just continue studies, hype the results and suck in more investors. This could go on for several years lining managements pockets.

[guardiangel]

They just want equipment..Right lol
There are two corporations, AMDL Inc. and Radient Pharmaceuticals. AMDL Australia is now AMDL Inc. DR-70 is still registered with AMDL Inc. DR-70 is under the AMDL Inc. corporation. Onko-Sure is still trademarked under the Radient Pharmaceutical Inc. umbrella. William and ProvistaDx will be taking over Radient for the lung cancer test.. The aussies have no shares..The creeping takeover group does, and they are Radient common shares..The aussies will most likely change the AMDL Inc. division, and become a subsidiary with Radient and remain a public non trading concern. They will change the name of the new subsidiary Minomic International Limited. They don't want equipment, they want DR-70 and partnerships in the USA per CLIA-ProvistaDx. imo Jonny Angel

Minomic International Limited will launch two overseas trials of its MiStat prostate cancer screening test, following an agreement with the prestigious CUSP Group, LLC.

http://www.cuspautism.com/what-we-do/

Company Name: CUSP GROUP, LLC
File Number: 5040565
Filing State: Delaware (DE)
Filing Status: Unknown
Filing Date: September 20, 2011




There is a poster who has claimed that the Tustin office was vacant a year ago..That is absolutely false..The last 8-K indicates that the offices and manufacturing facilities were still open on May 6, 2014..Here is the proof...Also there are selective former employees back on board..

http://www.sec.gov/Archives/edgar/data/838879/000114420414027804/v377522_8k.htm

"Despite significant financial hardship, the Company continues to maintain its offices and manufacturing facilities in Tustin, California, relying on selective former employees that continue to work as consultants."

The aussies along with Uni-Pharma will be a subsidiary of Radient. They are in control of DR-70 and the Dr-70 trademark..Living was right, they will combine Dr-70 with their reagents to get a 95 to 97 percent Specificity. That is why William and ProvistaDx are using DR-70 for the lung cancer test only according to their agreement.. imo Jonny Angel

On July 13, 2012, we(RADIENT) entered into a license agreement with Global Cancer Diagnostics, Inc. ("GCDx") in order to commercialize certain of our intellectual property in the form of a Lung Cancer test; the intellectual property at issue is specified in the Agreement and is herein referred to as the Licensed Products. Under the Agreement, GCDx will be the only company offering a test specific to lung cancer but will not make, use of or sell any of our other tests using the DR-70 reagents.

The aussies will be bringing Uni-pharma under the AMDL/Minomic subsidiary..AMDL Australia was the distributor of Onko-Sure in Australia and New Zealand..In the agreement between Uni and Radient, Uni is now the distributor and manufacturer via partnership.Uni Pharma is now the distributor of Onko_Sure in Australia and New Zealand..

On June 6th 2013, we entered into a 5-year license agreement between AMDL Diagnostics, Inc. (“ADI”), a division within our company, and Uni Pharma Co., Ltd. a Taipei Taiwan limited liability company (“UNI”) that provides UNI with a 5-year exclusive license (subject to automatic renewal for an additional 5 years) to RXPC’s Onko-Sure® (formerly called DR-70 cancer blood test kits (the “Tests”),

A division of a business or business division (sometimes[1] called a business sector[2]) is one of the parts into which a business, organization or company is divided.[3] The divisions are distinct parts of that business. If these divisions are all part of the same company, then that company is legally responsible for all of the obligations and debts of the divisions. However in a large organization, various parts of the business may be run by different subsidiaries, and a business division may include one or many subsidiaries. Each subsidiary is a separate legal entity owned by the primary business or by another subsidiary in the hierarchy. Often a division operates under a separate name and is the equivalent of a corporation or limited liability company obtaining a fictitious name or "doing business as" certificate and operating a business under that fictitious name. Companies often set up business units to operate in divisions prior to the legal formation of subsidiaries.


The patents were filed on September 14, 2011..The Cusp Group LLC was formed on September 20, 2011.

Radient Pharmaceuticals Files International Patents in Australia and New Zealand

Radient Pharmaceuticals Corporation September 14, 2011 7:00 AM

TUSTIN, CA--(Marketwire -09/14/11)- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC.PK - News) (Pinksheets: RXPC.PK - News), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.

"Building an intellectual property position in foreign markets protects and supports sales of our proprietary Onko-Sure® cancer test globally. Both Australia and New Zealand have highly developed healthcare markets where we believe Onko-Sure® can add value as a minimally invasive, relatively low cost cancer diagnostic," stated Radient Chairman and CEO Douglas MacLellan.

The Onko-Sure® test kit is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Blood samples can be run, in duplicate, for 40 people, on each test kit. Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection of 19 different cancers.